Johnson & Johnson Fate Therapeutics Inc Transaction History
Johnson & Johnson
- $297 Million
- Q2 2025
A detailed history of Johnson & Johnson transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Johnson & Johnson holds 3,379,064 shares of FATE stock, worth $3.18 Million. This represents 1.27% of its overall portfolio holdings.
Number of Shares
3,379,064
Previous 3,379,064
-0.0%
Holding current value
$3.18 Million
Previous $2.67 Million
41.78%
% of portfolio
1.27%
Previous 0.89%
Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
145Shares Held
82.8MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.1 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$8.24 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$4.27 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$3.19 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $91.2M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...